The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and
Agustín Tortajada1, Tamara Montes, Rubén Martínez-Barricarte
1Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Instituto Reina Sofía de Investigaciones Nefrológicas, Madrid, Spain.
Human Molecular Genetics
|June 25, 2009
Summary
The protective factor H (fH)-Ile(62) variant enhances C3b binding and inhibits complement proconvertase formation, offering protection against related diseases.
Area of Science:
- Complement system biology
- Molecular immunology
- Genetic polymorphisms and disease
Background:
- Factor H (CFH) gene mutations are linked to atypical hemolytic uremic syndrome, dense deposit disease, and age-related macular degeneration.
- Specific CFH variants differentially impact disease pathology, aiding in understanding pathogenesis.
- The factor H (fH)-Ile(62) polymorphism provides significant protection against these three diseases.
Purpose of the Study:
- To investigate the functional mechanism of the protective fH-Ile(62) polymorphism.
- To compare the C3b binding and complement regulatory activities of fH-Ile(62) and fH-Val(62) variants.
Main Methods:
- ELISA-based assays to measure C3b binding.
- Surface plasmon resonance (SPR) to analyze binding kinetics and competition with factor B.
- Functional assays assessing cofactor activity in factor I-mediated C3b cleavage and decay accelerating activity.
Main Results:
- The fH-Ile(62) variant exhibits enhanced binding to C3b compared to fH-Val(62).
- fH-Ile(62) demonstrates superior competition with factor B in proconvertase formation.
- Increased cofactor activity for fH-Ile(62) in C3b cleavage was observed, while decay accelerating activity remained similar between variants.
Conclusions:
- The protective effect of fH-Ile(62) stems from its improved ability to bind C3b, inhibit proconvertase formation, and enhance C3b inactivation.
- These findings illuminate the complement regulatory roles of factor H and offer insights for disease prediction and therapeutic development in complement-mediated disorders.
Related Concept Videos
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
01:57Protein Complexes with Interchangeable Parts
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
01:19Hypersensitivity Reactions: Immune-Complex Reactions
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
01:49Multiple Allele Traits
The Concept of Multiple Allelism